Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT2216 and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
NCT06964009Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DT2216 in ovarian cancer. Primary endpoints: Maximum Tolerated Dose at 42 days and Number of Participants Experiencing a Dose-Limiting Toxicity at 42 days. Started Sep 2025; status: recruiting.
02
Drugs
DT2216
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06964009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964009.